Rhythm Pharmaceuticals Inc (RYTM) concluded trading on Wednesday at a closing price of $89.0, with 4.79 million shares of worth about $426.01 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 49.28% during that period and on July 09, 2025 the price saw a gain of about 36.63%. Currently the company’s common shares owned by public are about 63.49M shares, out of which, 58.19M shares are available for trading.
Stock saw a price change of 36.00% in past 5 days and over the past one month there was a price change of 30.67%. Year-to-date (YTD), RYTM shares are showing a performance of 110.50% which increased to 58.99% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $40.61 but also hit the highest price of $69.89 during that period. The average intraday trading volume for Rhythm Pharmaceuticals Inc shares is 667.39K. The stock is currently trading 36.92% above its 20-day simple moving average (SMA20), while that difference is up 40.19% for SMA50 and it goes to 54.84% higher than SMA200.
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) currently have 63.49M outstanding shares and institutions hold larger chunk of about 95.48% of that.
The stock has a current market capitalization of $5.66B and its 3Y-monthly beta is at 2.37. It has posted earnings per share of -$2.82 in the same period. It has Quick Ratio of 3.13 while making debt-to-equity ratio of 13.60. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RYTM, volatility over the week remained 6.33% while standing at 4.26% over the month.
Analysts are in expectations that Rhythm Pharmaceuticals Inc (RYTM) stock would likely to be making an EPS of -0.62 in the current quarter, while forecast for next quarter EPS is -0.62 and it is -1.39 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.76 which is -0.49 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.55 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.52% while it is estimated to increase by 45.91% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on July 07, 2025 offering an Outperform rating for the stock and assigned a target price of $88 to it. Coverage by BofA Securities stated Rhythm Pharmaceuticals Inc (RYTM) stock as a Buy in their note to investors on April 07, 2025, suggesting a price target of $63 for the stock. On March 05, 2025, Stifel Resumed their recommendations, while on January 02, 2025, Jefferies Initiated their ratings for the stock with a price target of $80. Stock get an Outperform rating from Oppenheimer on December 20, 2024.
